KRAS, NRAS, BRAF, or HER2 testing of tumor tissue may be considered medically necessary for individuals with metastatic colorectal cancer to select individuals for treatment with FDA-approved therapies.
All other uses of KRAS, NRAS, BRAF, or HER2 testing of tumor tissue to guide colorectal cancer targeted therapy are considered investigational.
Circulating tumor DNA testing (liquid biopsy) to guide treatment in individuals with metastatic colorectal cancer is considered investigational. (see Policy Guidelines)
